Abstract
As academic researchers, some of us may be interested in forming start-up companies to develop and market the drugs that are based on our research. Others may be happy to license our technology and findings to an existing company. Knowing how to evaluate potential drug markets and effectively pitch to investors will help both groups of academicians. With so much intellectual property generated in academia, a well-researched commercial assessment and an organized and effective pitch can make potential licensees or investors take notice. The goal is not to recapitulate the sophisticated marketing plans drawn up in industry, but to highlight the project’s potential and show some industry savvy. This chapter provides guidance on evaluating the commercial potential of the project, pitching to potential licensees, approaching venture capitalists, and funding the development of not-for-profit programs. The chapter also discusses legal and practical considerations, should the academic decide to form a start-up company.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The contents of this publication are for informational purposes only. Neither this publication nor the lawyers who authored it are rendering legal or other professional advice or opinions on specific facts or matters. The authors and Orrick assume no liability in connection with the use of this publication.
IRS Circular 230 disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that any tax advice contained in this communication, unless expressly stated otherwise, was not intended or written to be used, and cannot be used, for the purpose of (1) avoiding tax-related penalties under the Internal Revenue Code or (2) promoting, marketing or recommending to another party any tax-related matter(s) addressed herein.
References
CDC press release recommending hepatitis C testing for US baby boomers. http://www.cdc.gov/nchhstp/newsroom/2012/HCV-Testing-Recs-PressRelease.html
Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R (2009) Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 3(8):e440
Moran M (2005) A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2(9):e302
Emmert-Buck MR (2011) An NIH intramural percubator as a model of academic-industry partnerships: from the beginning of life through the valley of death. J Transl Med 9:54
Moos WH, Kodukula K (2011) Nonprofit pharma: solutions to what ails the industry. Curr Med Chem 18(22):3437–3440
Olliaro P, Seiler J, Kuesel A, Horton J, Clark JN, Don R, Keiser J (2011) Potential drug development candidates for human soil-transmitted helminthiases. PLoS Negl Trop Dis 5(6):e1138
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mochly-Rosen, D., Grimes, K. (2014). Commercialization and Entrepreneurship. In: Mochly-Rosen, D., Grimes, K. (eds) A Practical Guide to Drug Development in Academia. SpringerBriefs in Pharmaceutical Science & Drug Development. Springer, Cham. https://doi.org/10.1007/978-3-319-02201-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-02201-7_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-02200-0
Online ISBN: 978-3-319-02201-7
eBook Packages: MedicineMedicine (R0)